Jump Financial’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-609,941
Closed -$8.69M 2055
2025
Q4
$8.69M Sell
609,941
-369,859
-38% -$3.63M 0.11% 244
2025
Q3
$7.72M Sell
979,800
-426,763
-30% -$3.04M 0.09% 276
2025
Q2
$8.06M Buy
1,406,563
+1,000,395
+246% +$6.46M 0.09% 290
2025
Q1
$3.31M Buy
406,168
+204,941
+102% +$1.9M 0.05% 432
2024
Q4
$1.9M Sell
201,227
-105,944
-34% -$1.1M 0.04% 533
2024
Q3
$3.28M Buy
307,171
+259,206
+540% +$2.82M 0.07% 341
2024
Q2
$476K Sell
47,965
-48,815
-50% -$501K 0.01% 1151
2024
Q1
$1.14M Sell
96,780
-115,521
-54% -$1.48M 0.03% 737
2023
Q4
$3.01M Sell
212,301
-25,088
-11% -$285K 0.1% 244
2023
Q3
$2.89M Buy
237,389
+153,282
+182% +$1.98M 0.11% 249
2023
Q2
$1.06M Sell
84,107
-83,540
-50% -$991K 0.04% 661
2023
Q1
$1.86M Buy
+167,647
New +$2.07M 0.08% 382
2022
Q4
Sell
-104,500
Closed -$1.09M 1727
2022
Q3
$1.09M Buy
104,500
+32,500
+45% +$362K 0.04% 591
2022
Q2
$773K Sell
72,000
-82,634
-53% -$680K 0.03% 677
2022
Q1
$1.46M Buy
154,634
+117,613
+318% +$1.1M 0.06% 374
2021
Q4
$428K Buy
+37,021
New +$413K 0.03% 723
2021
Q2
Sell
-81,910
Closed -$810K 1193
2021
Q1
$810K Buy
+81,910
New +$1.27M 0.08% 275

Other funds holding FOLD

Jump Financial's FOLD Position: Q1 2026 in Review

Jump Financial sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 609,941 shares — an estimated $8.69M sold.

Jump Financial first reported a position in FOLD in Q1 2021 and held it in 17 quarters. The position peaked at $8.69M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Jump Financial reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jump Financial sold 609,941 Amicus Therapeutics shares in Q1 2026, an estimated $8.69M.
  • Jump Financial first reported a position in Amicus Therapeutics in Q1 2021 and held it in 17 quarters.
  • Jump Financial's Amicus Therapeutics position peaked at $8.69M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.